CN113694065A - 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 - Google Patents

用于治疗非精神分裂症患者中的阴性症状的组合物和方法 Download PDF

Info

Publication number
CN113694065A
CN113694065A CN202111014262.XA CN202111014262A CN113694065A CN 113694065 A CN113694065 A CN 113694065A CN 202111014262 A CN202111014262 A CN 202111014262A CN 113694065 A CN113694065 A CN 113694065A
Authority
CN
China
Prior art keywords
compound
subject
composition
weeks
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111014262.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·鲁斯林格
M·达维德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of CN113694065A publication Critical patent/CN113694065A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202111014262.XA 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法 Pending CN113694065A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341590P 2016-05-25 2016-05-25
US62/341590 2016-05-25
CN201780045461.2A CN109689055A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780045461.2A Division CN109689055A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Publications (1)

Publication Number Publication Date
CN113694065A true CN113694065A (zh) 2021-11-26

Family

ID=58794265

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111014298.8A Pending CN113908156A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN201780045461.2A Pending CN109689055A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN202111014262.XA Pending CN113694065A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CN202111014298.8A Pending CN113908156A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
CN201780045461.2A Pending CN109689055A (zh) 2016-05-25 2017-05-23 用于治疗非精神分裂症患者中的阴性症状的组合物和方法

Country Status (9)

Country Link
US (2) US20190216793A1 (enExample)
EP (1) EP3463356A1 (enExample)
JP (3) JP2019516756A (enExample)
KR (2) KR20240005110A (enExample)
CN (3) CN113908156A (enExample)
PH (1) PH12018502445A1 (enExample)
SG (2) SG11201810358YA (enExample)
TW (2) TWI820001B (enExample)
WO (1) WO2017205393A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018501217A (ja) 2014-12-02 2018-01-18 田辺三菱製薬株式会社 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
PE20200732A1 (es) 2017-06-21 2020-07-23 Minerva Neurosciences Inc Formas de dosificacion oral y de liberacion controlada gastrorresistentes
GB2591667A (en) * 2018-08-21 2021-08-04 Minerva Neurosciences Inc Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
TWI879755B (zh) * 2020-02-20 2025-04-11 日商田邊三菱製藥股份有限公司 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途
KR102360137B1 (ko) * 2020-03-25 2022-02-08 주식회사 케이티앤지 카트리지 및 이를 포함하는 에어로졸 생성 장치
JP2024508660A (ja) * 2021-02-09 2024-02-28 ゼノン・ファーマシューティカルズ・インコーポレイテッド 快感消失の治療に使用するための電位依存性カリウムチャネル開口薬
WO2024138073A1 (en) * 2022-12-21 2024-06-27 Woebot Labs, Inc. Administering a digital therapeutic using a device interface to treat anxiety or depression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1260512B1 (en) * 2000-02-29 2007-07-04 Mitsubishi Pharma Corporation Novel cyclic amide derivatives
TW200616608A (en) * 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
JP2009525979A (ja) * 2006-02-07 2009-07-16 田辺三菱製薬株式会社 ４−アシルアミノピリジン誘導体を介した神経新生
JP2008273954A (ja) * 2007-03-30 2008-11-13 Mitsubishi Tanabe Pharma Corp うつ病の予防及び／又は治療剤
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
DK3135286T3 (da) * 2010-07-20 2023-11-27 Minerva Neurosciences Inc Fremgangsmåder til anvendelse af cykliske amidderivater til behandling af skizofreni og symptomer derpå
PL2595485T3 (pl) * 2010-07-20 2022-06-20 Minerva Neurosciences, Inc. Sposoby zastosowania pochodnych amidów cyklicznych w leczeniu zaburzeń mediowanych przez receptor sigma
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
JP6531093B2 (ja) * 2014-05-16 2019-06-12 武田薬品工業株式会社 含窒素複素環化合物
JP2018501217A (ja) * 2014-12-02 2018-01-18 田辺三菱製薬株式会社 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン

Also Published As

Publication number Publication date
WO2017205393A1 (en) 2017-11-30
TW201808288A (zh) 2018-03-16
TW202335672A (zh) 2023-09-16
PH12018502445A1 (en) 2019-09-09
US20230190726A1 (en) 2023-06-22
US20190216793A1 (en) 2019-07-18
TWI820001B (zh) 2023-11-01
CN113908156A (zh) 2022-01-11
JP2022188185A (ja) 2022-12-20
CN109689055A (zh) 2019-04-26
TWI851224B (zh) 2024-08-01
JP2019516756A (ja) 2019-06-20
JP2025000921A (ja) 2025-01-07
SG11201810358YA (en) 2018-12-28
SG10202011470UA (en) 2021-01-28
EP3463356A1 (en) 2019-04-10
KR20240005110A (ko) 2024-01-11
KR20190013846A (ko) 2019-02-11

Similar Documents

Publication Publication Date Title
US11680044B2 (en) Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
TWI820001B (zh) 醫藥組成物的用於製造非思覺失調症病患之負性症狀治療劑的用途
US20250000881A1 (en) Treatment of treatment resistant depression with psilocybin
CA3255654A1 (en) Treatment of postnatal depression
HK1207593A1 (en) Medicament for treating mental and behavioural disorders
JP2022526101A (ja) 重水素化デキストロメトルファン及びキニジンを使用して統合失調症の陰性症状を治療する方法
KR20240122455A (ko) 치료-저항성 우울증의 치료에서 사용하기 위한 실로사이빈 및 보조적 세로토닌 재흡수 저해제
CN119497589A (zh) 用于设计和产生增进人际亲密感心智状态的治疗组合、组合物和方法
WO2025068714A1 (en) Pharmaceutical compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt)
JP6585598B2 (ja) 注意欠陥及び／又は多動の治療における使用のためのベンゾジオキソール誘導体
CN120641095A (zh) 精神障碍的治疗
CN118488843A (zh) 用赛洛西宾治疗难治性抑郁症
EP4522176A1 (en) Selective dopamine increase
CA3255635A1 (en) TREATMENT OF MENTAL DISORDERS
HK1184674B (en) Treatment for neurological and mental disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination